1005407-55-5Relevant articles and documents
Discovery of clinical candidate GSK1842799 As a selective S1P1 receptor agonist (prodrug) for multiple sclerosis
Deng, Hongfeng,Bernier, Sylvie G.,Doyle, Elisabeth,Lorusso, Jeanine,Morgan, Barry A.,Westlin, William F.,Evindar, Ghotas
, p. 942 - 947 (2013/10/22)
To develop effective oral treatment for multiple sclerosis (MS), we discovered a series of alkyl-substituted biaryl amino alcohols as selective S1P1 modulators. One exemplar is (S)-2-amino-2-(5-(4-(octyloxy)-3- (trifluoromethyl)phenyl)-1,3,4-th